

COVID-19 Ag



10-19

GenBody COVID-19 Aq

Gentody Inc.

 $(\in G)$


MID-19 C€

GenBody COVID-19 Ag Detection kit for SARS-CoV-2 antigen


The pandemic of COVID-19 has been already announced by WHO (World Health Organization). The symptoms of COVID-19 are diverse, but generally include fatigue, fever, cough, loss of smell and taste and breathing difficulties. The symptoms of COVID-19 start to show in the period of 1 to 14 days after exposure to the virus. Even though the molecular test (RT-PCR) has become the standard method for the diagnosis of this disease, a lot of clinic systems need more simple and convenient methods due to several limitations of molecular test.

GenBody COVID-19 Ag is an immunochromatographic assay kit for the qualitative detection of SARS-CoV-2 antigen in nasopharyngeal and oropharyngeal swab from human. This kit is simply used to detect the SARS-CoV-2 virus, providing results in 10 to 20 mins. One of the best advantages of this kit is inexpensive despite high sensitivity and specificity.

Assay Procedure




Interpretation of the Results



Diagnosis of GenBody COVID-19 Ag kit for the SARS-CoV-2 variants

- Current variants of SARS-CoV-2: mainly mutated in spike protein (SP).
- Total 23 mutated positions by SNPs (single-nucleotide polymorphisms) or deletion.
- Very less or none mutations of the nucleoprotein (NP) of SARS-CoV-2.



- Target protein of GenBody COVID-19 Ag is NP of SARS-CoV-2 in human respiratory specimens.
 → No effect to diagnose from these kinds of SARS-CoV-2 variants.
- In summary, GenBody COVID-19 Ag can surely detect the current variants of SARS-CoV-2.
 - 1. Leonid Y. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell (2020) 183, p739-751.
- 2. Andrew R. et al. Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. nCoV-2019 Genomic Epidemilology (2020) https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563

Clinical evaluation

• Under the strict IRB regulation, we collected and performed the clinical studies using total 506 patient's samples (493 specimens : $Ct \le 30$, 13 specimens : Ct > 30) which were confirmed to be COVID-19 positive and its negative in Korea (2 sites) and in USA (1 site). The method of confirmation was RT-PCR kit (Korean/US FDA-EUA approved).

n = 493 (Ct ≤ 30)		Molecular te	Total	
		Positive	Negative	TULGI
GenBody COVID-19 Ag	Positive	119	4	123
	Negative	4	366	370
Total		123	370	493

Sensitivity = 96.83% (95% CI: 92.07% to 99.%), (Ct > 30: Less than 50%) Specificity = 99.18% (95% CI: 97.25% to 99.59%)

PPV (Positive Predictive Value) =

Specificity = 99.18% (95% CI: 97.25% to 99.59%)		96.83%NPV (Negative Predictive Value)				
	Real-Time PCR					
n = 285		Positive			Negative	Total
		Asymptomatic	*Day 1~6	*Day 7~	Negative	
GenBody COVID-19 Ag	Positive	5	48	24	3	80
	Negative	1	4	3	197	205
Total		6	52	27	200	285

*Day after the onset of symptoms.

Sensitivity = 83.3% (Asymptomaticcases)

- 92.3% (95% CI = 81.5% to 97.9%) at Day 1~6
- 88.9% (95% CI = 70.8% to 97.7%) at after Day 7

Ordering Information

	Cat no.	Product Name	Package	Box Size (mm)	Carton Size(mm)
C	OVAG025	GenBody COVID-19 Ag	25 Tests/Kit	250 x 125 x 90	570 x 390 x 520



[•] Specificity = 98.5% (95% CI = 95.7% to 99.7%)